Reuters logo
BRIEF-Probiodrug: Last Patient Last Visit reached in Saphir study
April 7, 2017 / 5:18 AM / 6 months ago

BRIEF-Probiodrug: Last Patient Last Visit reached in Saphir study

April 7 (Reuters) - Probiodrug AG:

* Last patient last visit (LPLV) reached in Saphir study

* Key results for primary endpoint of safety/tolerability and for components of three exploratory endpoints - cognition, EEG/FMRI and main molecular biomarkers expected early June 2017 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below